Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Heijmen, Linda ^a   Ter Voert, Edwin E G W ^a   Oyen, Wim J G ^a   Punt, Cornelis J A ^b   Van Spronsen, Dick Johan ^c   Heerschap, Arend ^a   De Geus Oei, Lioe Fee ^a,d   Van Laarhoven, Hanneke W M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IOVERSOL; OXALIPLATIN; UFT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG DISTRIBUTION; DRUG RESPONSE; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; COLORECTAL NEOPLASMS; LIVER TUMOR; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; SCINTISCANNING; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; COLORECTAL NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84926617527     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120823     Document Type: Article

References (31)

1. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. AnnSurg. 2006;244:254-259. PMID: 16858188
2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2010;92:205-216.
3. Desar IM, Van Herpen CM, Van Laarhoven HW, Barentsz JO, Oyen WJ, Van Der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. CancerTreat Rev. 2009;35:309-321. doi: 10.1016/j.ctrv. 2008.12.001 PMID: 19136215
4. Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21:309-315. doi: 10.1016/j.suronc.2012.07.003 PMID: 22884035
5. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010;32:437-453. doi: 10.1016/j.clinthera.2010.03.012 PMID: 20399983
6. De Geus-Oei LF, Vriens D, Van Laarhoven HW, Van Der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J NuclMed. 2009;50 Suppl 1:43S-54S. doi: 10.2967/jnumed.108.057224 PMID: 19403879
7. De Geus-Oei LF, Wiering B, Krabbe PF, Ruers TJ, Punt CJ, Oyen WJ. FDG-PETfor prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol. 2009;17:1650-1655.
8. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Ruhl A, Irngartinger G, Stremmel W, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480-1487. PMID: 15347714
9. Hendlisz A, Golfinopoulos V, Garcia C, Covas A, Emonts P, Ameye L, et al. Serial FDG-PET/CTfor early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol. 2012;23:1687-1693. doi: 10.1093/annonc/mdr554 PMID: 22112970
10. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR AmJ Roentgenol. 2007;188:1622-1635. PMID: 17515386
11. Heijmen L, Verstappen MCHM, Ter Voert EEGW, Punt CJA, Oyen WJG, De Geus-Oei LF, et al. Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Critical Reviews in Oncology/Hematology. 2012;83:194-207. doi: 10.1016/j.critrevonc.2011.12.008 PMID: 22269446
12. Yablonskiy DA, Sukstanskii AL. Theoretical models of the diffusion weighted MR signal. NMR Biomed. 2010;23:661-681. doi: 10.1002/nbm.1520 PMID: 20886562
13. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology. 2009;248:894-900.
14. Koh DM, Scurr E, Collins D, Kanber B, Norman A, Leach MO, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol. 2007;188:1001-1008. PMID: 17377036
15. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur Radiol. 2007;17:861-872. PMID: 17043737
16. Fan B, Wang XY, Yang XD, Zhong H, Wu CX, Jiang XX. Blood oxygen level-dependent MRI for the monitoring of neoadjuvant chemotherapy in breast carcinoma: initial experience. Magn Reson Imaging. 2011;29:153-159. doi: 10.1016/j.mri.2010.08.014 PMID: 21129879
17. Chavhan GB, Babyn PS, Thomas B, Shroff MM, Haacke EM. Principles, techniques, and applications of T2∗-based MR imaging and its special applications. Radiographics. 2009;29:1433-1449. doi: 10. 1148/rg.295095034 PMID: 19755604
18. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Strobands SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200. doi: 10.1007/s00259-009-1297-4 PMID: 19915839
19. Ter Voert EE, Van Laarhoven HW, Kok PJ, Oyen WJ, Visser EP, De Geus-Oei LF. Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in 18F-FDG PET/CT. Nucl MedCommun. 2014;35:472-477 doi: 10.1097/MNM.0000000000000086 PMID: 24509519
20. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J NuclMed. 2009;50 Suppl 1:122S-150S. doi: 10.2967/jnumed. 108.057307 PMID: 19403881
21. Frings V, De Langen AJ, Smit EF, Van Velden FH, Hoekstra OS, Van Tinteren H, et al. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLTPETin non-small cell lung cancer. J Nucl Med. 2010:51:1870-1877. doi: 10.2967/jnumed.110.077255 PMID: 21078791
22. De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, et al. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer. 2012;106:1926-1933. doi: 10.1038/bjc.2012.184 PMID: 22596235
23. Hambrock T, Somford DM, Huisman HJ, Van Oort IM, Witjes JA, Hulsbergen-Van De Kaa CA, et al. Relationship between Apparent Diffusion Coefficients at 3.0-T MR Imaging and Gleason Grade in Peripheral Zone Prostate Cancer. Radiology. 2011;259:453-461 doi: 10.1148/radiol.11091409 PMID: 21502392
24. Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, Tani A, et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl MedMol Imaging. 2010;37:2011-2020. doi: 10.1007/s00259-010-1529-7 PMID: 20607535
25. Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF 2nd. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage oftumoron core biopsy. AJRAm J Roentgenol. 2010;194:W316-322. doi: 10. 2214/AJR.09.2651 PMID: 20308476
26. Liu CJ, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, et al. The efficacy of chemotherapy in patients with high-grade metastatic colon cancer. Hepatogastroenterology. 2011;58:1495-1501. doi: 10.5754/hge11082 PMID: 21940314
27. Nanni O, Volpi A, Frassineti GL, De Paola F, Granato AM, Dubine A, et al. Role of biological markers in the clinical outcome of colon cancer. Br J Cancer. 2002;87:868-875. PMID: 12373601
28. Heijmen L, Ter Voert EGW, Punt C. J. A., Punt C. J. A., HA, Bussink J, Sweep CG, et al. Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media and mol imaging. 2014;9:237-245. doi: 10.1002/cmmi.1564 PMID: 24700751
29. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hickish T, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700-708. PMID: 8622014
30. Desar IM, Van Laarhoven HW, Hambrok T, Ter Voert E, Van Der Graaf WT, et al. Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in renal cell carcinoma (RCC) by dynamic contrast enhanced MRI (DCE-MRI) and diffusion weight MRI (DWI) at3tesla (T). ASCO annual meeting 2010. Abstract number 3051.
31. Li SP, Taylor NJ, Makris A, Ah-See ML, Beresford MJ, Stirling JJ, et al. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology. 2010;257:643-652. doi: 10.1148/radiol.10100421 PMID: 20858850